|
gptkb:NTLA-5001
|
gptkb:United_States
|
|
gptkb:NKX101
|
Phase 1
|
|
gptkb:ViaCyte
|
type 1 diabetes
|
|
gptkb:IMR-687
|
Phase 2
|
|
gptkb:umibecestat
|
discontinued
|
|
gptkb:idasanutlin
|
Phase II
|
|
gptkb:lisocabtagene_maraleucel
|
gptkb:TRANSCEND_NHL_001
|
|
gptkb:CoviVac
|
Phase III (as of 2021)
|
|
gptkb:CK-1827452
|
Phase 3
|
|
gptkb:IL2RG_gene
|
genetic testing for SCID
|
|
gptkb:Skycovione
|
Phase 3
|
|
gptkb:KRX-0401
|
Phase II
|
|
gptkb:SCN1A
|
genetic testing for epilepsy
|
|
gptkb:YBB-202
|
Phase 1
|
|
gptkb:APG-1252_(Bcl-2/Bcl-xL_inhibitor)
|
Phase I/II
|
|
gptkb:Erythrocytes
|
Complete blood count
|
|
gptkb:KSQ_Therapeutics
|
KSQ-4279 for solid tumors
|
|
gptkb:Pfizer-BioNTech
|
July-November 2020
|
|
gptkb:Relacorilant
|
Phase 3 (Cushing's syndrome)
|
|
gptkb:Anktiva_(N-803)
|
Phase 3
|